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Editorial on the Research Topic
Hemostasis and Stroke
Stroke is the leading cause of death and permanent disability worldwide (1, 2). Understanding the
hemostasis system in stroke presents an exciting and relatively new area of research with potential
applications in stroke therapy (3–5). Better understanding of the alterations of the hemostasis
system, particularly its counterplay with inflammation and vascular biology has tremendous
potentials in stroke management. In this Special Issue, original research articles and reviews focus
on most recent advances on hemostasis, thrombosis or vascular biology related to all areas of
stroke research.
Hemorrhagic transformation (HT) after ischemic stroke is a common and potentially severe
complication (6). HT carries a high risk of clinical deterioration and is associated with poor
outcomes and mortality (7). Early recognition or prediction of HT would be an important aid
for the appropriate management of AIS patients. Due to the importance of this topic, it is not
surprising that a series of papers in this Special Issue aimed to improve our understanding of
HT. In the research paper by He et al. the authors investigated whether an easily accessible
and rapid screening tool, the neutrophil-platelet ratio (NPR) could predict HT in patients with
AIS. In theory, NPR shows its advantage in revealing information about the crosstalk between
inflammation and hemostasis. Based on a cohort of 279 stroke patients, the authors conclude that
high NPR (>39.9) was independently associated with the increased risk of HT, particularly that
of parenchymal hematoma in AIS (OR = 2.00, 95%CI: 1.041–3.843, p = 0.037). Not only low
platelet count, but impaired platelet function may also increase the risk of HT. Rapid testing of
platelet count is a well-established standard in the treatment of AIS and patients with low platelet
counts are excluded from recombinant tissue plasminogen activator (rt-PA) treatment due to the
significantly increased risk of HT (8). Although current guidelines do not recommend it, whether
platelet function testing could be used to guide treatment decision during the acute phase of AIS
is unknown (9). In the study by Lieschke et al. the authors aimed to demonstrate the feasibility of
incorporating flow cytometry-based platelet function testing in a mouse model of dual antiplatelet
therapy followed by ischemic stroke and rt-PA infusion (Yuan et al.). In addition to monitoring
the efficacy of antiplatelet therapy, they sought to investigate the impact of platelet function in
the development of HT. Their results suggest that reduced platelet activation is indicative of an
increased risk for HT following experimental stroke and rt-PA treatment. Another important factor
that might contribute to HT in AIS patients could be the impaired hemostasis balance due to liver
fibrosis. The paper by Yuan et al. highlights that although subclinical liver fibrosis or steatosis
may not be rare in patients with stroke, data are lacking regarding the association between liver
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fibrosis and HT for patients with AIS (10). In their single
center retrospective study, 185 consecutive patients with HT
and 199 age- and sex-matched AIS patients without HT were
enrolled, and the extent of liver fibrosis was assessed using a
validated fibrosis index (FIB-4). After adjustments for potential
confounders, the authors concluded that AIS patients with a high
FIB-4 score had a 3.461-fold risk (95%CI: 1.404–8.531) of HT as
compared to patients with low FIB-4 score. HT may be a rare
but severe complication of adult ischemic Moyamoya disease
(MMD) (11). In the research paper by Lu et al. the authors
investigated the differences of clinical and radiological features
between adult ischemic MMD patients with and without HT
and studied clinical outcomes. Their data suggest that normal
cerebral perfusion may be a risk factor associated with HT in
adult ischemic MMD. As expected, HT was strongly associated
with increased disability rates and mortality in the investigated
cohort of patients.
HT following AIS may be facilitated by rt-PA therapy. rt-
PA has been the mainstay of therapeutic thrombolysis in AIS,
however, in ∼6–8% of treated patients, potentially devastating
intracerebral hemorrhage may occur (12). Moreover, rt-PA
may have other effects on the central nervous system by
modulating the blood brain barrier (BBB) permeability and
influencing neuroinflammatory processes (13). These include the
complement system that has received much attention in CNS
disorders in recent years. While the role of the complement’s
cascade in neuroinflammation, neurodegenerative disease, and
CNS injury is well-recognized, its role in rt-PA mediated
neuroinflammation and stroke has not been fully explored as
yet. Tenecteplase (TNK-tPA) is a challenging alternative of rt-PA,
developed over 25 years ago to circumvent the short half-life of
t-PA (14). Parallel studies on TNK-tPA is important in studies
attempting to investigate the efficacy and safety of rt-PA. In their
original work, Keragala et al. demonstrate that inhibition of the
complement C5a-C5R1 interaction reduces the ability of rt-PA
and TNK-r-PA to increase BBB permeability, which may offer
novel means to improve the safety profile of thrombolytic therapy
for patients with AIS.
HT and the increase of BBB permeability is not the
only concern in patients receiving thrombolytic agents.
Unfortunately, the majority of patients who receive thrombolysis
using rt-PA fail to recanalize and lack neurological improvement
(15). In the study protocol described by Lilicrap et al., the
authors hypothesize that individual plasmin potential, as
measured by in vitro response to rt-PA, may serve as a
biomarker of rt-PA response and patients with greater plasmin
response are more likely to recanalize early (Lillicrap et al.).
Their study will be based on historical samples from the
Barcelona Stroke Thrombolysis Biobank, comprised of 350
pre-thrombolysis plasma samples from AIS patients who
received serial transcranial Doppler measurements before
and after thrombolysis. The primary outcome of the study
will be time to recanalization detected by TCD (defined
as TIBI ≥ 4). Results of this study may have important
implications for the clinical practice: if association between
proteolytic response to rt-PA and recanalization is confirmed,
future clinical treatment may customize thrombolytic therapy
to maximize outcomes and minimize adverse effects for
individual patients.
Interestingly, our knowledge today is still limited about
hemostasis alterations increasing the risk of stroke. In this
Special Issue, informative case reports are published on
inherited and acquired thrombophilic risk factors associated
with stroke (Watanabe et al. and Huseynov et al.). Cases of
cyclosporine A induced intracranial thrombotic complications
and a systematic review of the literature is provided by Song
et al., reviewing articles on cyclosporine A- related thrombotic
events and summarizing features of clinical characteristics
and neuroimaging findings in drug-induced cerebral venous
thrombosis. Significant sex-differences in risk factors for
transient ischemic attack (TIA) were found and published in this
Special Issue by Wang et al. by screening a high-risk population
of >230,000 residents in eastern China. This original work
highlights that improving the understanding of sex differences
in the prevalence of stroke risk factors is necessary to develop
strategies to reduce stroke incidence and mortality. The research
paper by Fang et al. aimed to investigate the association between
intracranial atherosclerotic stenosis (ICAS) and the severity
of white matter changes (WMC). Their work may improve
our understanding regarding how the presence of ICAS would
influence the progression of WMC, which could potentially
provide future therapeutic opportunities for prevention.
In the past few years, new perspectives were opened in
the field of thrombosis and vascular biology, when mechanical
thrombectomy has permitted the histological analysis of retrieved
thrombi of AIS patients. In depth characterization of the
structure of ischemic stroke thrombi may serve as an important
tool to provide useful insights on AIS pathomechanisms and
treatment failure (16). In this Issue, two relevant papers
were published assessing cellular, hemostatic and protein
components of AIS thrombi. In their original research paper,
Dargazanli et al. resolved the proteomes of cardioembolic and
atherothrombotic cerebrovascular human thrombi and applied
an artificial intelligence routine to examine protein signature
between the two selected groups. Marta-Enguita et al. performed
histological analysis of different hemostatic parameters including
some key proteins, potentially determining thrombus stability
that have not been investigated as yet: thrombin activatable
fibrinolysis inhibitor (TAFI) and matrix metalloproteinase 10
(MMP-10). The authors report that histological composition
and distribution of different thrombi hemostasis components
have prognostic implications, and it could potentially have an
impact on the strategies to guide personalized therapies for
stroke patients.
Hemorrhagic stroke accounts for ∼10–15% of all strokes and
results in a higher rate of mortality as compared to ischemic
strokes (17). In the IRONHEART study, published as a study
protocol by Árokszállási et al.. and an original research paper
by Orbán-Kálmándi et al. the authors aimed to test whether
various hemostasis parameters may predict the outcome of non-
traumatic intracerebral hemorrhage (ICH). Their results show
that a modified clot lysis assay, that incorporates the effect
of neutrophil extracellular traps correlated with the estimated
bleeding volumes in patients with ICH and might serve as
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a useful tool to predict ICH outcomes. It is known that
about 10% of intracerebral neoplastic lesions initially present as
spontaneous ICH (18). In the work of Nawabi et al., the authors
evaluated the potential of a machine learning-based prediction
of etiology for acute ICHs based on quantitative radiomic
image features extracted from initial non-contrast-enhanced
tomography (NECT) brain scans. The quantitative evaluation of
acute NECT images in a machine learning algorithm provided
high discriminatory power in predicting non-neoplastic vs.
neoplastic ICH, thus the authors suggest that using this approach
in the clinical routine might improve patient care. Treatment
options in ICH are often challenging due to the high mortality
of this disorder (19). The paper by Apostolaki-Hansson et al.
investigated whether the effect of oral anticoagulant (OAC)
treatment reversal is beneficial in patients with ICH. They
compared 90-day survival and outcome in patients with OAC-
ICH who received OAC reversal therapy and those who did
not using the database of The Swedish Stroke Register. Their
results showed that patients receiving OAC-reversal treatment
had an improved 90-day mortality outcome as compared to those
not receiving treatment. Their results warrant larger studies to
determine which patient groups are likely to benefit from reversal
therapy. Another paper by Zhou et al. tested whether minimally
invasive surgery or conservative treatment is more beneficial
for patients with ICH. In their review paper, trial sequential
analysis was applied on data from randomized trials to answer
this question. They conclude that minimally invasive surgery is
more effective than conservative treatment in patients with ICH
in reducing morbidity and mortality. Repeating a clinical trial
with similar devices, design and outcomes is unlikely to change
current evidence.
We are confident that the papers in this Special Issue
will be of interest and relevance to those involved in the
experimental and clinical fields related to stroke and hemostasis.
We hope that the published articles will provide ideas and
inspiration to those dedicated to understanding the risk factors,
pathophysiology and treatment outcomes of stroke in order to
better diagnose, treat or prevent this devastating disorder in
the future.
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